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Abstract
Background & Aims—A balance between effector and regulatory (Treg) T-cell responses is
required to maintain intestinal homeostasis. To regulate immunity, T cells migrate to the intestine
using a combination of adhesion molecules and chemokine receptors. However, it is not known
whether the migration pathways of effector cells and Tregs are distinct or shared. We sought to
determine whether interaction between the chemokine CCR9 and its receptor, CCL25, allows
effectors or Tregs to localize to chronically inflamed small intestine.
Methods—Using a mouse model that develops Crohn's-like ileitis (TNFΔARE mice) we
examined the role of CCL25–CCR9 interactions for effector and Treg traffic using flow
cytometry, quantitative reverse transcription PCR, immunohistochemistry, immunoneutralization,
and proliferation analyses.
Results—In TNFΔARE mice, expression of CCL25 and the frequency of CCR9-expressing
lymphocytes increased during late-stage disease. In the absence of CCR9, TNFΔARE mice
developed exacerbated disease, compared with their CCR9-sufficient counterparts, which
coincided with a deficiency of CD4+/CD25+/FoxP3+ and CD8+/CD103+ Tregs within the
intestinal lamina propria and mesenteric lymph nodes. Furthermore, the CD8+/CCR9+ subset
decreased the proliferation of CD4+ T cells in vitro. Administration of a monoclonal antibody
against CCR9 to TNFΔARE mice exacerbated ileitis in vivo, confirming the regulatory role of
CD8+/CCR9+ cells.
Conclusions—Signaling of the chemokine CCL25 through its receptor CCR9 induces Tregs to
migrate to the intestine. These findings raise concerns about the development of reagents to
disrupt this pathway for the treatment of patients with Crohn's disease.
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Introduction
CD and ulcerative colitis result from an imbalance between effector and Treg responses1.
Although agents that target lymphocyte recirculation have proven therapeutic efficacy in CD
(e.g. Natalizumab)2, none specifically target the traffic of effector T cells, while sparing that
of Tregs. Further understanding of the mechanisms that mediate effector and Treg
recirculation may result in the development of novel therapeutics with better specificity than
those in clinical use.
Lymphocyte recirculation to the intestine is mediated by integrin α4β7, which interacts with
Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1)3. However, it is not known
how T cells recognize specifically the small intestinal microenvironment to maintain the
preferential small intestinal localization observed in CD. The expression of CCL25 (TECK)
is restricted to the small intestine and thymus, providing a potential molecular mechanism
for a trafficking dichotomy into distinct small and large intestinal compartments4.
CCL25 attracts cells that express its cognate receptor CCR9. This might be of clinical
relevance, as patients with small intestinal CD have increased numbers of CCR9+ T cells in
blood5. CCL25 is additionally induced in the liver of patients with primary sclerosing
cholangitis6. Thus, it is conceivable that CCL25 serves as a chemoattractant for effector
CCR9+ T cells or alternatively, CCL25 may recruit Tregs to help dampen dysregulated
inflammation. Consistent with this hypothesis, Papadakis et al. recently identified a CCR9+
T cell population that produces IL-107.
Preliminary trial data (PROTECT1) suggests that a small molecule inhibitor of CCR9
(CCX282, Traficet-EN, ChemoCentryx) might have a therapeutic effect in CD8. However,
CCR9 deficiency had no effect on the severity of ileitis in TNFΔARE mice9, whereas
Traficet EN prevented disease onset. Thus, there is disagreement between the existing
preclinical and clinical evidence.
The TNF ΔAU-rich element (TNFΔARE) model develops terminal ileitis, reminiscent of
human CD in its histological features and the pivotal role played by TNF in its
pathogenesis10. Thus, we further explored the role of the CCR9/CCL25 axis for the
trafficking of T cells in this model, as it is the first chemokine and receptor pair that may
account for the lifelong terminal ileal localization shared with the human disease. First, we
assessed the expression of CCR9 and CCL25 along the time course of the disease. We then
generated CCR9-deficient TNFΔARE mice and assessed the severity of ileitis, noticing
increased severity, when compared to CCR9-sufficient TNFΔARE mice. Thus we
hypothesized that Tregs might be more dependent on CCL25/CCR9 than effectors for
homing into small bowel. To further explore this possibility we assessed the frequency of
Tregs in CCR9-sufficient and deficient mice and investigated a potential role for CCR9-
expressing CD8+ T cells in the regulation of Crohn's-like ileitis. Finally, the effect of CCR9
immmunoneutralization on disease severity was evaluated.
Results
Increased frequency of CCR9-expressing T cells in lymphoid compartments of TNFΔARE
mice
The expression of CCR9 was assessed by flow cytometry in T cells isolated from the spleen,
MLN and LP of TNFΔARE mice (solid line) during early (4-), peak (8-)(not shown) and late
disease (≥20-weeks-of-age), compared with WT littermates (gray histograms)(Figure 1A).
Corresponding isotype antibodies (not shown) and CCR9-deficient lymphocytes
(discontinuous histograms) were used as controls. At 4- and at 8-weeks-of-age, we observed
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that the percentage of CCR9-expressing cells was not significantly different (not shown).
However, at 20-weeks-of-age the absolute counts, calculated by multiplying the percentage
positive cells by the cell counts of the organs (see supplementary methods), revealed a
significant increase in CD4+/CCR9+ in TNFΔARE mice spleen (3±0.3×106 vs. 5±0.7×106,
P=0.03), MLN (0.6±0.7×106 vs. 2±0.2×106, P<0.001) and LP (1.4±0.1×106 vs. 3±0.3×106,
P=0.005) compared with WT mice.
Both the percentage (P<0.05) and absolute numbers (26±1×106 vs. 18±2×106, P=0.01) of
CD8+/CCR9+ T cells from 20-week-old TNFΔARE mice were lower in the spleen
compared with WT. In contrast, within the MLN both the percentage (P<0.01) and absolute
counts increased nearly five-fold (2±2×106 vs. 8.5±0.2×106, P<0.001). Within the LP both
the percentage (P<0.05) and absolute counts (1±0.2×106 vs. 3±0.4×106, P=0.02) of CD8+/
CCR9+ T cells also increased (Figure 1A). Thus there is redistribution of CCR9-expressing
CD8+ T cells and accumulation within the ilea and MLN in mice with ileitis.
Ileal expression of CCL25 increased in TNFΔARE mice
To determine whether CCL25 expression was modulated by inflammation, we assessed
mRNA transcripts and protein levels in WT and TNFΔARE mice. CCL25 mRNA levels
showed a decreasing gradient from proximal to distal small intestine in WT mice11. By
contrast, expression in ilea from 20-week-old TNFΔARE mice was increased four-fold
compared to WT littermates (Figure 1B, P<0.001). CCL25 was not significantly different at
4 weeks, regardless of the mRNA source, but was increased 4-fold at 20-weeks-of-age in
whole ilea (Figure 1C, P<0.05) and 15-fold in enriched epithelial extract (Figure 1D,
P<0.001). Immunohistochemistry confirmed that CCL25 protein localized predominantly to
epithelia and increased at 20- compared with 4-week-old mice. Preincubation of the primary
with recombinant CCL25 confirmed the specificity of the signal (Figure 1E, control) and no
signal was observed in sections incubated with the secondary without preincubation with the
primary (not shown). Thus, expression of CCL25 increased specifically in inflamed terminal
ilea and is restricted to intestinal epithelia.
CCR9 deficiency exacerbates chronic murine Ileitis
It has been recently reported that CCR9 deficiency had no effect on the severity of TNF-
driven ileitis in TNFΔARE mice9. This result was unexpected as CCR9/CCL25 are believed
to play a critical role for small intestinal homing12. Thus, we generated CCR9-deficient
TNFΔARE mice13. The full spectrum of disease (early, peak, late) was evaluated in CCR9-
sufficient (ΔARE) and CCR9-deficient (ΔARE/CCR9-/-) mice (Figure 2A). Active indices
revealed more severe ileitis at 4-weeks-of-age in ΔARE/CCR9-/- compared with ΔARE
mice, at 8- and at 20-weeks-of-age. A significant increase in the chronic index was also
observed at 8- and at 20-weeks-of-age in ΔARE/CCR9-/- mice. Villus distortion was
significantly different at 20-weeks-of-age, whereas higher total indices were observed in
ΔARE/CCR9-/- mice at all time points assessed: 4-(0.7±0.2 vs. 0.2±0.1, P<0.05), 8-(18±1
vs. 14±2, P<0.05) and 20-weeks-of-age (22±1.3 vs. 16±1.3, P<0.01) (Figure 2A).
Representative micrographs showed distortion of intestinal architecture and more
pronounced transmural infiltrates in ΔARE/CCR9-/- mice compared with TNFΔARE mice
(Figure 2B). Thus, CCR9 deficiency exacerbates TNF-mediated ileitis.
Decreased CD4+/CD25+/FoxP3+ Tregs in the MLN and LP of ΔARE/CCR9-/- mice
To examine whether Tregs rely on CCR9/CCL25 interactions to traffic to ileum and MLN in
ileitis we assessed the frequency of CD4+/CD25+/FoxP3+ Tregs in ΔARE/CCR9-/- mice
compared with WT and ΔARE mice (Figure 3). The percentage of Tregs increased in the
spleen of 20-week-old ΔARE mice compared with WT littermates but not in 8-week-old
mice. Within this compartment, there was no difference in the percentage of Tregs in CCR9-
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sufficient or -deficient TNFΔARE mice at 8- and 20-weeks-of age. Yet in the MLN, Tregs
increased at 8 weeks in ΔARE mice compared with WT (10±0.2 vs. 14±0.7, P<0.01) and
decreased back to the level of WT mice in ΔARE/CCR9-/- mice (12±0.1, P<0.05 vs.
ΔARE). Also at 20-weeks-of-age Tregs increased in ΔARE MLN compared to controls
decreasing in frequency in ΔARE/CCR9-/- mice. This was also the case in the LP, where
Tregs increased at 8 weeks in ΔARE mice compared with WT and decreased in ΔARE/
CCR9-/- mice and at 20-weeks (Figure 3A). Representative contour plots highlight the
relative deficiency of Tregs in ΔARE/CCR9-/- mice (Figure 3B). Normalization by cell
count confirmed these differences (not shown). Thus, Tregs accumulate in the inflamed
MLN and LP of TNFΔARE mice compared with WT controls whereas this is not observed
in CCR9-deficient animals, despite their more severe inflammation.
Increased CD8+/CD44+ effectors and decreased CD8+/CD103+ T cells during peak and
chronic disease in CCR9-deficient TNFΔARE mice
We and others have previously described the effector functions of CD8+/CD44+ T cells in
TNFΔARE mice and shown that CD44 deficiency attenuates ileitis14, 15. Conversely CD8+/
CD103+ T cells inhibit the proliferation of CD4+ T cells in vitro and reduced their ability to
induce ileitis in vivo16. Thus an imbalance of these populations may lead to exacerbation of
IBD. To determine the effect of inflammation and CCR9 deficiency on the distribution of
these subsets, we examined their frequency in WT, ΔARE and ΔARE/CCR9-/- mice. We
observed increased effector CD8+/CD44+ T lymphocytes in the spleen of ΔARE compared
with WT and a further increase in ΔARE/CCR9-/- at 8- and 20-weeks-of-age. Also within
the LP there were significant increases in CD8+/CD44+ T cells between ΔARE and ΔARE/
CCR9-/- mice at both 8- and 20-weeks-of-age (Figure 4A, C).
Conversely, CD8+/CD103+ T cells decreased in ΔARE/CCR9-/- mice spleen compared with
ΔARE at 8-(49±3 vs. 51±3, N.S. vs. 30±6, P<0.05) and at 20-weeks-of-age. In the MLN
there was an increase in CD8+/CD103+ T cells between WT and ΔARE, but no change in
ΔARE/CCR9-/- at 8 weeks (59±2 vs. 69±3, P<0.05 vs. 69±2, N.S.), whereas at 20-weeks-of-
age the CD8+/CD103+ subset increased in ΔARE compared to WT mice and decreased in
ΔARE/CCR9-/- mice. Within the LP the CD8+/CD103+ T cells increased between WT and
ΔARE mice and decreased in ΔARE/CCR9-/- at 8-(40±1 vs. 63±4, P<0.05 vs. 47±2, P<0.05)
and 20-weeks-of-age (Figure 4B). Representative contour plots demonstrate that CCR9
deficiency results in an imbalance between effector and regulatory subsets in ΔARE/CCR9-/-
mice (Figure 4C).
Preferential CCR9 expression by CD4+/CD25+/FoxP3+ and CD8+/CD103+ Treg cells
As Tregs failed to accumulate within the LP of CCR9-deficient mice relative to CCR9-
sufficient mice (Figures 3, 4), we examined whether such impairment may be due to their
reliance on CCR9 to home to small intestine. We compared the surface expression of CCR9
in regulatory subsets to those of cells not expressing Treg markers in 20-week-old
TNFΔARE mice. The percentage of CCR9-expressing cells was higher in CD4+/CD25+/
FoxP3+ Treg cells from spleen (red histogram) compared with their CD4+/CD25neg/
FoxP3neg T cell counterparts (blue histogram). Expression within MLN was also higher and
the LP yielded similar results (Figure 5A). Furthermore, within CD8+/CD103+ T cells (red
histogram) the percentage of CCR9-expressing cells was higher compared with CD8+/
CD44+ T cells (blue histogram) in spleen, MLN and in LP (Figure 5B). Cells isolated from
CCR9-deficient mice (discontinuous histograms) served as controls. Together this data show
that CCR9 is preferentially expressed by Tregs in TNFΔARE mice and explains the
deficiency of CD4+/FoxP3+ and CD8+/CD103+ T cells in the ileal LP of ΔARE/CCR9-/-
mice.
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CD8+/CCR9+ T cells from TNFΔARE mice decreased proliferation of CD4+ T cells in a dose-
dependent manner
We have previously shown that the CD8+/CD103+ subset inhibit CD4+ T cell proliferation
in vitro and induction of ileitis in vivo16. Here we additionally show that fifty to eighty
percent of these cells co-express CCR9 (Figure 5). To further assess a potential regulatory
role of the CD8+/CCR9+ subset, we investigated whether the CD8+/CCR9+ T cells isolated
from TNFΔARE mice (Figure 6A), could affect the proliferation of CD4+ T cells after anti-
CD3/CD28 stimulation. We observed strong proliferation of CD4+ T cells when cultured
alone. Addition of a 10:1 CD4+:CD8+/CCR9+ ratio significantly reduced proliferation of
CD4+ T cells between 27 and 61% in cell divisions 1 and 4. A 5:1 ratio reduced proliferation
from 40 to 74% and a 1:1 ratio maximally inhibited proliferation between 56 and 90%
(Figure 6B, C and supplementary table 1). A 1:1 ratio of CD8+/CCR9+ T cells was required
to reduce the proliferation of CD4+ T cells if isolated from WT mice, suggesting that the
pro-inflammatory environment present in TNFΔARE mice enhances the anti-proliferative
capacity of this T cell subset, as we have shown previously for CD4+ T cells from
TNFΔARE mice (supplementary Figure 1)16. Thus, CD8+/CCR9+ T cells (particularly those
isolated from TNFΔARE mice) exert a potent anti-proliferative effect on CD4+ T cells.
Anti-CCR9 mAb exacerbates ileitis in TNFΔARE mice and depletes CD8+/CD103+Tregs
To evaluate the effect of an anti-CCR9 mAb on the severity of ileitis, we administered mAb
CW1.2 or its equivalent IgG2a isotype to 4-week-old TNFΔARE mice. Terminal ilea were
harvested and the severity of ileitis was assessed, as described17. Treatment with anti-CCR9
mAb significantly worsened active, chronic, villus and total indices (3±1 vs. 9±0.4,
P<0.001) compared with isotype-treated controls (Figure 7A). Flow cytometry analyses
showed no significant change in the frequency of CD4+/CD25+/FoxP3+ Tregs, whereas
within the CD8+, the CD44+ subset increased while the CD103+ T cells decreased in mice
treated with anti-CCR9 mAb compared with isotype-treated mice (P<0.05 vs. isotype for all
organs)(Figure 7B). Thus, targeting the CCR9/CCL25 pathway alters the ratio of effector
and regulatory CD8+ T cells and exacerbates ileitis.
Discussion
Imprinting of T cells with a small intestinal homing address code (i.e. CCR9) is mediated by
retinoic acid (RA)18. RA in the presence of TGF-β additionally determines the induction of
FoxP319, while TGF-β also promotes the expression of CD10320. Yet although the induction
of these regulatory molecules shares common pathways, little is known about the role of the
CCL25/CCR9 axis for Treg trafficking and regulation of immune responses in the small
intestine. Here we show high concordant expression of CCR9, FoxP3, and CD103 in Tregs,
suggesting that their induction might be coupled within inductive compartments. As CCL25
expression is restricted to small intestine, we evaluated its role in the TNFΔARE model that
develops inflammation in the distal small intestine. We show that CCR9+ T cells undergo
late inflammation-driven expansion. Furthermore, during late disease, the amount of CCR9
mRNA transcripts and CCL25 protein levels increased in TNFΔARE mice ilea, yet CCL25
protein expression remained localized to the ileal epithelium. Evaluation of disease severity
in CCR9-deficient mice revealed more severe disease than that of CCR9-sufficient
counterparts. Thus, we investigated whether a preferential dependence by Tregs on the
CCR9/CCL25 axis for homing into the chronically-inflamed ileum may account for the
accelerated disease. We noticed a deficiency of CD4+/CD25+/FoxP3+ and CD8+/CD103+
Tregs within the LP and MLN of CCR9-deficient mice. In addition, Tregs preferentially
expressed CCR9 on their surface than their non-regulatory counterparts and the CD8+/
CCR9+ subset decreased the proliferation of CD4+ T cells in vitro. Moreover, anti-CCR9
antibodies exacerbated disease and altered the pro- to anti-inflammatory CD8+/
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CD44+:CD8+/CD103+ T cell ratio, confirming a predominant role for CCR9/CCL25 for the
regulation of ileitis.
CCR9-expressing cells are increased in peripheral blood of patients with small bowel CD5,
thus inflammatory signals might modulate their frequency. The expression of CCR9 is
known to be induced by RA18, while a high antigen dose is suppressive21. It is not known
whether inflammatory signals (e.g. cytokines) might alter CCR9 expression. Our data
suggests that during the late disease of TNFΔARE mice either CCR9 is induced
(predominantly in CD8+ T cells) or survival/retention signals result in increases in the
number of CCR9-expressing cells within the MLN and LP. Furthermore it appears that
CCR9 might be upregulated as the CD8+ T cells migrate out of the LP into the MLN and the
periphery. Thus, CCR9 expression appears to be a dynamic process, with cells being able to
upregulate and downregulate surface expression perhaps after ligand binding, resulting in
internalization, as shown with other chemokine receptors (e.g. CCR7). This may account for
the lower mean fluorescence intensities observed in the LP22. As we utilized CCR9-
deficient lymphocytes as controls and two different mAb clones, our studies convincingly
report the true expression of this molecule within the different subsets and lymphoid
compartments.
As it has been shown for other chemokines, CCL25 is likely transcytosed across
endothelium to be presented at the apical surface23 where it induces adhesion of CCR9-
expressing cells24. Although CCL25 has been considered a homeostatic chemokine25 more
recent data have led to the suggestion that its expression may be inducible in intestinal
inflammation26, 27. CCL25 is additionally expressed aberrantly in the liver of patients with
primary sclerosing cholangitis6. Yet the specific inflammatory signals that induce its
expression in intestine or liver remain to be defined. Ericsson and colleagues exposed small
intestinal cell lines to TNF and IFN-γ and mice to LPS in vivo and although they observed
increased expression of other chemokines, CCL25 remained unchanged28. Although our
data might suggest that TNF (overproduced systemically in TNFΔARE mice), might be
responsible, we observed localized induction within the affected terminal ileum rather than
generalized small bowel expression, suggesting that perhaps a combination of mediators
within the effector organ triggers expression.
Few studies have looked at the role of CCL25/CCR9 pathway in models of IBD and the
limited available literature appears discordant. We have previously evaluated its role in the
SAMP1/YitFc model, which spontaneously develops Crohn's-like ileitis and found that the
therapeutic efficacy of CCR9 immunoblockade was limited to early disease27. However,
other work has shown that CCR9 deficiency had no effect on the severity of ileitis in
TNFΔARE mice9, whereas a small molecule inhibitor of CCR9 prevented disease onset29.
By contrast our studies in TNFΔARE mice showed that CCR9 deficiency exacerbates ileitis.
Several differences may account for the discrepancy. First, we evaluated the entire course of
the disease from 4- to 20-weeks-of-age, whereas the prior study evaluated disease between
8- and 14-weeks-of-age. Second, while the prior study evaluated the histological severity of
disease in cohorts of 3-6 mice, our experimental cohorts included a minimum of 17 mice9.
Finally, in our studies all mouse strains were on C57BL6/J background and the genetic
background affects the severity of IBD in animal models30.
Tregs, defined by their expression of the transcription factor forkhead box P3 (FoxP3)31 and
production of IL-10 accumulate in intestine of patients with IBD32. Expansion of CD4+/
FoxP3+ T cells has also been reported in animal models33. The molecular basis of their
recruitment to the inflamed small intestine has yet to be elucidated. There is evidence to
support that CD4+/CD25+/FoxP3+ cells from the small intestinal LP may express more
CCR9 on their surface than similar cells from the spleen34 and a subset of CD4+/CCR9+
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cells possesses a Treg cytokine profile7. We hypothesized that Treg deficiency in CCR9
deficient mice, due to an increased Treg dependence on CCR9 to traffic to the ileum resulted
in exacerbated inflammation. In fact Treg frequency in CCR9-deficient mice was similar to
that of controls and lower than in TNFΔARE mice, despite their worse inflammation,
supporting a reliance on CCR9/CCL25 for Treg traffic to the inflamed small intestine.
CD8+ T cell subsets in TNFΔARE mice have either an effector or a regulatory
function14, 15,16. The latter are characterized by expression of CD103 16 which is present
murine and human CD8+ T cells that home to mucosal surfaces. CD4+ T cells that express
CD103 exert a regulatory role in colitis35. We have previously described that the CD8+/
CD103+ subset inhibited the proliferation of CD4+ cells in vitro and exerted a regulatory
role during TNF-mediated ileitis16. Here we observe an imbalance between these subsets in
CCR9-deficient TNFΔARE mice, which exhibited increased proinflammatory CD8+/CD44+
T cells while displaying decreased pro-regulatory CD8+/CD103+. This imbalance has
implications on the course and severity of disease due to the large disparity between effector
and regulatory subsets in CCR9-deficient TNFΔARE mice.
CD45Rbhigh T cells induce colitis in RAG-deficient or SCID mice30, whereas co-transfer of
Tregs prevented and cured IBD33, highlighting the critical role of Tregs for maintenance of
homeostasis. Lymphocyte recruitment to the small intestine requires local expression of
CCL25 that interacts with CCR9 on the T cell surface. However, little is known about the
specific homing determinants of Tregs. We show that in TNFΔARE mice, CD4+/CD25+/
FoxP3+ and CD8+/CD103+ Tregs show preferential expression of CCR9 compared with
their non-regulatory counterparts. The potential dependency on this pathway by Tregs for
recirculation to terminal ileum may contribute to the observed exacerbation of disease
resulting from genetic ablation of CCR9.
We confirmed that CCR9-expressing CD8+ T cells inhibited the proliferation of CD4+ T
cells in a dose-dependent manner. To further define whether this was also true in vivo we
tested the effect on an anti-CCR9 mAb on disease severity. Antibody treatment significantly
worsened all histological parameters and significantly reduced the percentage of the CD8+/
CD103+ Tregs in ilea and MLN and increased the effector CD8+/CD44+ subset, confirming
a critical role for CCR9-expressing cells for the regulation of ileitis.
Recent trials examined the efficacy of Traficet EN, CCX282-B, which targets the CCL25/
CCR9 axis in patients with CD8. The preliminary results appear promising both for
induction and maintenance of remission
(http://www.drugs.com/clinical_trials/chemocentryx-reports-traficet-maintains-remission-
crohn-s-digestive-week-ddw-2010-conference-9318.html,
http://www.medicalnewstoday.com/articles/172216.php). In addition, preclinical data on the
preventive effect of Traficet EN has been published36. As the chemokine is not expressed in
normal or inflamed colon, it is interesting that the above studies did not focused on patient
with ileitis but also included colonic and ileocolonic CD. Our observations of exacerbated
disease and decreased Tregs after treatment with an anti-CCR9 mAb or genetic ablation of
CCR9 supports the hypothesis that CCR9 plays a major role in the trafficking of Tregs to the
chronically inflamed small intestine. Thus, the CCR9/CCL25 axis appears to be more
important for the regulation of immune responses than for its induction in this TNF-
mediated ileitic model.
Wermers et al. Page 7
Gastroenterology. Author manuscript; available in PMC 2012 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Materials and Methods
Mice
The B6.129S-Tnftm2Gkl/Jarn strain was generated as previously described14, backcrossed to
C57BL6/J for over 30 generations and kept under specific pathogen-free conditions.
Experimental animals were either heterozygous for the ΔARE mutation or homozygous
wild-type (WT), which served non-inflamed controls. CCR9-deficient TNFΔARE mice
were generated from CCR9-deficient mice13 by mating TNFΔARE males to CCR9-/-
females on C57BL6/J background for 2 or more generations. CCR9 deficiency was
confirmed by genotyping the progeny and by flow cytometry on isolated T cells. Fecal
samples were negative for Helicobacter, protozoa and helminthes. All animals were handled
according to procedures approved by the institutional committee for animal use.
Tissue collection and histological analyses
The distal ilea (10 cm) were harvested and histological assessment of ileal inflammation was
performed by a single pathologist (PJ) in a blinded fashion, using a semi-quantitative
scoring system, as described17.
Real-Time RT-PCR
CCL25 transcript quantification was performed using TaqMan assays (Mm00436443_m1,
Applied Biosystems, Foster City, CA) using an ABI PRISM 7300 Sequence Detection
System. Each reaction was performed in duplicate. Thermocycling conditions were as per
manufacturer's instructions (TaqMan Reagents, product insert). The expression of 18s
(Hs99999901-s1, Applied Biosystems) was measured as an endogenous control. The ratio of
messenger RNA expression was calculated by the ΔΔCt method (user bulletin no. 2, Applied
Biosystems).
Immunohistochemistry
Terminal ilea were snap frozen, sectioned (5 μm), fixed with acetone and incubated with
goat polyclonal anti-CCL25 (AF-481, R&D Systems, Minneapolis, MN) or goat IgG, with
or without recombinant mouse CCL25 (R&D Systems). Rabbit anti-goat horseradish
peroxidase–labeled antibody was used as secondary (Vector Laboratories, Burlingame, CA).
Normal rabbit sera was used to reduce nonspecific binding (Sigma Chemical Co, St Louis,
MO).
Lymphocyte isolation
Splenocytes, MLN, and lamina propria mononuclear cells were isolated as previously
described27.
Flow cytometry and intracellular staining
Cells were incubated with fluorescent rat or hamster anti-mouse antibodies with the
following specificities CD4 (GK1.5, RM4-5), CD8 (53-6.7), CD19(6D5), CD25 (PC61),
CD44 (IM7), CD62L (MEL-14), CD103 (2E7), (BD Biosciences, San Jose CA, USA),
FoxP3 (FJK-16s)(e-Biosciences, San Diego CA), and CCR9 (242503) (R&D Systems) or
CW-1.2 (e-Biosciences). FoxP3 staining was performed as per manufacturer's instructions
(e-Biosciences). Additional controls included cells isolated from CCR9-deficient mice while
positive controls were collected from WT thymi. Cells were washed and fixed with 2%
paraformaldehyde and seven/eight color analyses were performed using the BD FACSCanto
II (BD Biosciences). Cell sorting was performed using the Moflo XDP (Beckman Coulter,
Inc, Fullerton, CA). Further analyses were performed using FLOWJo software (Tree Star
Inc, Ashland, OR).
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In vitro T cell proliferation assay
Splenic and MLN CD4+ and CD8+/CCR9+ T cells were isolated from TNFΔARE mice,
CD19+ cells were depleted using anti-mouse CD19 microbeads (Miltenyi Biotec, Auburn,
CA). The flow-through was stained with anti-mouse CD4, anti-mouse CD8 and anti-mouse
CCR9. CD4+ and CD8+/CCR9+ subsets were separated using a Moflo XDP fluorescence-
activated cell sorter (Beckman Coulter). CD4+ T cells were stained with CFSE (0.5 μM) and
1×106 cells/well were stimulated with anti-CD3/CD28 Dynabeads (Invitrogen, Carlsbad,
CA) and cultured for 5 days alone or with CD8+/CCR9+ T-cells (≥97% pure). Cells were
stained with anti-CD4 and analyzed by flow cytometry. Cell proliferation was quantified
using the cell proliferation analysis function of FlowJo software (Tree Star Inc.).
Treatment study
TNFΔARE mice received three intraperitoneal doses (200μg) of anti-CCR9 mAb(clone CW
1.2) or isotype every other day for three days. Organs were collected 24 h after the last
injection.
Statistics
Statistical analyses were performed using the two-tailed Student's T test. Data were
expressed as mean ± standard error of the mean (S.E.M.). Statistical significance was set at
P<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
CCR9 and CCL25 expression in TNFΔARE mice and WT controls. (A) CCR9 expression
was analyzed by flow cytometry using CCR9-deficient lymphocytes (dashed line) and
isotype-matched antibody (MFI<101, not shown) as controls. Cells were gated on FSC, SSC,
CD4 or CD8 (Mean ± S.E.M. percent positive and representative histograms obtained from
4 or more independent experiments, n=3-4 mice/time point and strain). (B, C, D) CCL25
transcripts were quantified by real-time RT PCR (Mean ± S.E.M. fold differences n=5-7
mice/intestinal segment/strain/time point, *P<0.05, ***P<0.001). (E)
Immunohistochemistry showed CCL25 protein expression. Preincubation with recombinant
CCL25 was used as control (Representative micrographs from 3 experiments, 10×
magnification, bars=100μm).
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Figure 2.
CCR9 deficiency exacerbated Ileitis. (A) Disease severity in TNFΔARE+/-/CCR9+/+
(ΔARE) and TNFΔARE+/-/CCR9-/-(ΔARE/CCR9-/-) mice was assessed at indicated ages
(Mean ± S.E.M, n=17-20 mice/strain/time point, *P<0.05, **P<0.01). (B) Representative
micrographs, hematoxylin and eosin, 10× magnification, bars=100μm.
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Figure 3.
CD4+/CD25+/FoxP3+ Tregs decreased in MLN and LP during peak and late disease in
CCR9-deficient TNFΔARE mice. Lymphocytes isolated from indicated compartments of
WT, ΔARE and ΔARE/CCR9-/- mice were incubated with indicated antibodies and analyzed
by flow cytometry, gating on FSC, SSC and CD4. (A) (Mean ± S.E.M. from 6 independent
experiments, n=3-4 mice/time point/strain run in duplicate, *P<0.05, **P<0.01,
***P<0.001). (B)Representative contour plots at 20-weeks-of-age.
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Figure 4.
Imbalance of CD8+/CD44+ and CD8+/CD103+ T cells in CCR9-deficient TNFΔARE mice.
Lymphocytes from WT, ΔARE and ΔARE/CCR9-/- mice were incubated with indicated
antibodies and analyzed by flow cytometry after gating on FSC SSC and CD8. (A, B)
Percentage of CD8+/CD44+ and CD8+/CD103+ T cells in lymphoid compartments at
indicated ages (Mean ± S.E.M. from 6 independent experiments, *P<0.05, **P<0.01).
(C)Representative contour plots from CD8+ T cells at 20-weeks-of-age.
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Figure 5.
CCR9 is preferentially expressed by Tregs. (A, B) CCR9 expression was assessed in CD4+/
CD25+/FoxP3+ (red histograms) and in CD8+/CD103+ (red histograms) compared to that of
CD4+/CD25neg/FoxP3neg and CD8+/CD44+ (blue histograms) using cells isolated from
CCR9-deficient mice (discontinuous histograms) as controls (Mean ± S.E.M. from 4
experiments, n=3 mice/experiment). Representative contour plots from TNFΔARE mice and
similarly derived histograms from CCR9-deficient mice gated on FSC, SSC, CD4 and CD8.
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Figure 6.
CD8+/CCR9+ T cells decreased proliferation of CD4+ T cells. (A) CD4+ and CD8+/CCR9+
lymphocytes were isolated by flow cytometric sorting as illustrated. (B) CFSE-labeled CD4+
T cells were cultured with or without increasing ratios of CD8+/CCR9+ T cells. Proliferation
was assessed by flow cytometry. (C)Quantification of areas under the curve was performed
using FlowJo cell proliferation analysis software (Mean ± S.E.M. from 2 independent
experiments run in triplicate, ***P<0.001).
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Figure 7.
Anti-CCR9 mAb exacerbated ileitis and reduced CD8+/CD103+ Tregs. (A) TNFΔARE mice
received isotype or anti-CCR9 mAb. The severity of ileitis was assessed as described17
(Mean ± S.E.M., n=5 mice/group, **P<0.01, ***P<0.001). (B) Lymphocytes from isotype-
and anti-CCR9-treated mice were incubated with indicated antibodies and analyzed by flow
cytometry. Cells were gated on FSC, SSC and CD8 (Mean ± S.E.M., P<0.05 vs. isotype).
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